natgillin/translations-raw huggingface dataset:
Method as claimed in claim 1, wherein said electromagnetic waves have a frequency comprised within the microwave range. 
Postupak sukladno zahtjevu 1, pri čemu elektromagnetski valovi imaju frekvenciju sadržanu unutar opsega mikrovalova.
Method as claimed in claim 5, wherein the microwave frequency ranges from 0,915 to 5,8 GHz. 
Postupak sukladno zahtjevu 5, pri čemu je opseg frekvencije mikrovalova od 0,915 do 5,8 GHz.
Method as claimed in one of claims 5 and 6, wherein said microwave irradiation is performed in a substantially constant fashion, for a predetermined time (T), ranging from a few seconds to 2 minutes, and preferably less than 1 minute. 
Postupak sukladno jednom od zahtjeva 5 i 6, pri čemu je iradijacija mikrovalova izvedena na supstancijalno konstantni način, kroz prethodno određeno vrijeme (T), opsega od 2 minute, i poželjno manje od 1 minute.
Method as claimed in claim 1, wherein said electromagnetic field has a specific power (P) ranging from 50 to 300 W per gram of powdered product, preferably of about 150 W per gram of powdered product. 
Postupak sukladno zahtjevu 1, pri čemu elektromagnetsko polje ima specifičnu snagu (P) opsega od 50 do 300 W po gramu praškastog proizvoda, poželjno oko 150 W po gramu praškastog proizvoda.
Method as claimed in claim 1, wherein said moistening step c) is carried out by adding a predetermined amount of water to the powered product, and possibly further adding binders, followed by a homogenization step, which is carried out by mixing, to obtain a substantially uniform moistened mixture. 
Postupak sukladno zahtjevu 1, pri čemu se korak vlaženja c) izvodi dodavanje prethodno određene količine vode praškastom proizvodu, i po mogućnosti dodavanjem vezivnih sredstava, praćeno korakom homogenizacije, koji se izvodi miješanjem, radi dobivanja u osnovi jednolične vlažne mješavine.
Method as claimed in claim 9, wherein said predetermined amount of water ranges from 2% to 20% and is preferably about 10% by weight of the dry powdered product. 
Postupak sukladno zahtjevu 9, pri čemu je prethodno određena oličina vode opsega od 2% do 20% poželjno oko 10% mase suhog praškastog proizvoda.
Method as claimed in one or more of the preceding claims, wherein said energy supply step f) is followed by a short rest step h) for the tablet, which is in turn followed by a step in which the latter undergoes individual or multiple packaging i). 
Postupak sukladno jednom ili više prethodnih zahtjeva, pri čemu je korak opskrbe energijom f) praćen kratkim korakom odmora h) tablete, koji je praćne korakom u kojem posljednja prolazi postupak pojedinačnog ili pakiranja više tableta zajedno i).
Method as claimed in one or more of the preceding claims, wherein the product to be ground is selected from the group comprising coffee, barley, malt, ginseng, tea, infusions and other similar brewable food products. 
Postupak sukladno jednom ili više prethodnih zahtjeva, pri čemu je proizvod koji će biti samljeven odabran iz skupine koja obuhvaća kavu, ječam, slad, ginseng, čaj, infuzije i ostale druge prehrambene proizvode koje je moguće zakuhati.
compression means (8, 108) associated with said hollow body (4, 104) for compressing the powdered product dose collected therein and forming a tablet (C) having a desired shape; 
kompresijska sredstva (8, 108) povezana s navedenim šupljim tijelom (4, 104) za komprimiranje doze praškastog proizvoda i formiranje tablete (C) željenog oblika;
Arrangement as claimed in claim 13, wherein said compression means (8, 108) comprise a piston that is slidably and sealingly arranged within said inner cavity (5, 105) and is designed to be externally driven to compress the powdered product dose by means of its longitudinal travel. 
Uređaj sukladno zahtjevu 13, pri čemu navedena kompresijska sredstva (8, 108) obuhvaćaju polugu koja je klizno i s mogućnošću zatvaranja smještena unutar unutarnje šupljine (5, 105) i dizajnirana je da bude u pogonu izvana kako bi se komprimiralo dozu praškastog proizvoda posredstvom longitudinalnog kretanja.
Small installation according to claim 1 or 2, characterized by that, the material of the small installation (1) is plastic, preferably 6-8 mm thick polypropylene plate, which is welded with known plastic welding technology, and that its material can also be stainless steel or polyester. 
Mala instalacija prema patentnom zahtjevu 1 ili 2, naznačena time da je, materijal male instalacije (1) plastičan, poželjne debljine polipropilen ploče 6-8 mm, koja je zavarena poznatom tehnologijom varenja plastike i da njen materijal također može biti od nehrđajućeg čelika ili poliestera.
Small installation according to any of the claims 1 - 3, characterised by that, a portion of the stable sludge is removed on a regular basis, as a result of which the sludge load of the system is significantly lower, and the micro-bubble air blower (13) required in the aerobic space (4) can have a smaller capacity. 
Mala instalacije prema bilo kojem od patentnih zahtjeva 1 - 3, naznačena time da je, dio čvrstog mulja uklonjen na redovnoj osnovi, kao rezultat od kojeg je opterećenje mulja u sistemu značajno niže, i zračni kompresor za stvaranje mikro mjehurića (13) zahtjevan u aerobnom prostoru (4) može da ima manji kapacitet.
Small installation according to any of the claims 1 - 6, characterised by that, the material of the sludge bag (71) is water permeable material, preferably woven polypropylene, woven jute, preferably made of decomposable material. 
Mala instalacija prema bilo kojem od patentnih zahtjeva 1-6, naznačena time da je, materijal vreće za mulj (71) materijal koji propušta vodu, poželjno tkani polipropilen, tkana juta, poželjno napravljen od razgradivog materijala.
providing an aqueous solution derived from calcium carbonate, wherein the aqueous solution comprises dissolved calcium carbonate and reaction species thereof, and wherein the concentration of calcium carbonate in the solution is from 0.1 to 1 g/L, and 
osiguravanje vodene otopine dobivene od kalcijevog karbonata, pri čemu vodena otopina sadrži otopljeni kalcijev karbonat i njegove reakcijske vrste, te pri čemu je koncentracija kalcijevog karbonata u otopini od 0.1 do 1 g/L, i
preparing an aqueous suspension of calcium carbonate in a first step, and introducing either: (i) a carbon dioxide generating compound, (ii) a carbon dioxide generating compound and an acid, or (iii) an acid to an aqueous suspension of calcium carbonate in a second step, or 
pripremanje vodene suspenzije kalcijevog karbonata u prvom koraku, i uvođenje bilo: (i) spoja koji stvara ugljikov dioksid, (ii) spoja koji stvara ugljikov dioksid i kiseline, ili (iii) kiseline u vodenu suspenziju kalcijevog karbonata u drugom koraku, ili
introducing in a first step either: (i) a carbon dioxide generating compound, (ii) a carbon dioxide generating compound and an acid, or (iii) an acid in the water to be used for the preparation of the solution, and then introducing calcium carbonate, either in dry form or as a suspension in a second step in the water, or 
uvođenje u prvom koraku bilo: (i) spoja koji stvara ugljikov dioksid, (ii) spoja koji stvara ugljikov dioksid i kiseline, ili (iii) kiseline u vodu koja će se koristiti za pripremanje otopine, i zatim uvođenje kalcijevog karbonata, bilo u suhom obliku ili kao suspenzije u drugom koraku u vodu, ili
dolomitic limestone, calcareous dolomite or half burnt dolomite, magnesium oxide such as burnt dolomite, magnesium sulfate, potassium hydrogen carbonate, or sodium hydrogen carbonate. 
dolomitni vapnenac, vapnenački dolomit ili polu žareni dolomit, magnezijev oksid kao što je žareni dolomit, magnezijev sulfat, kalijev hidrogen karbonat, ili natrijev hidrogen karbonat.
The process of any of the previous claims, wherein the remineralized water has a Silt Density Index SDI15 below 5, preferably below 4, and most preferred below 3. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da remineralizirana voda ima indeks gustoće mutnoće SDI15 ispod 5, poželjno ispod 4, te najpoželjnije ispod 3.
The process of any of the previous claims, wherein the remineralized water has a Membrane Fouling Index MFI0.45 below 4, preferably below 2.5, most preferred below 2. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da remineralizirana voda ima indeks onečišćenja membrane MFI0.45 ispod 4, poželjno ispod 2.5, najpoželjnije ispod 2.
measuring a parameter value of the remineralized water, wherein the parameter is selected from the group comprising alkalinity, total hardness, conductivity, calcium concentration, pH, CO2 concentration, total dissolved solids, and turbidity of the remineralized water, 
mjerenje parametarske vrijednosti remineralizirane vode, pri čemu je parametar odabran i skupine koju čine alkalnost, ukupna tvrdoća, vodljivost, koncentracija kalcija, pH, koncentracija CO2, ukupne otopljene krute tvari, te zamućenost remineralizirane vode,
comparing the measured parameter value with a predetermined parameter value, and 
uspoređivanje izmjerene parametarske vrijednosti s predodređenom parametarskom vrijednosti, te
introducing in a first step either: (i) a carbon dioxide generating compound, (ii) a carbon dioxide generating compound and an acid, or (iii) an acid in the water to be used for the preparation of the solution, and then introducing calcium carbonate, either in dry form or as a suspension in a second step in the water, or 
uvođenje u prvom koraku ili: (i) spoja koji stvara ugljikov dioksid, (ii) spoja koji stvara ugljikov dioksid i kiseline, ili (iii) kiseline u vodu koja će se koristiti za pripremanje otopine, te zatim uvođenje kalcijevog karbonata, bilo u suhom obliku ili kao suspenzije u drugom koraku u vodu, ili
The use of claim 17, wherein the remineralized water is selected from drinking water, recreation water such as water for swimming pools, industrial water for process applications, irrigation water, or water for aquifer or well recharge. 
Uporaba prema zahtjevu 17, naznačena time da je remineralizirana voda odabrana od vode za piće, vode za rekreaciju kao što je voda za bazene, industrijske vode za primjenu u industrijskim procesima, vode za navodnjavanje, ili vode za vodonosnike ili dopunjavanje bunara.
A compound of formula (I) as indicated below: 
Spoj formule (I), kao što je prikazano niže:
Rb is selected from the group consisting of hydrogen, C1-4 alkyl, and aryl C1-4 alkyl 
Rb se bira iz skupine koju čine vodik, C1-4 alkil i aril C1-4 alkil;
is selected from the group consisting of hydrogen, and C1-4 alkyl; 
se bira iz skupine koju čine vodik i C1-4 alkil;
A compound, or a pharmaceutically acceptable salt thereof, for use according to claim 6, wherein the disease is chronic obstructive lung disease. 
Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što je bolest kronična opstruktivna plućna bolest.
A non-virion particle that does not comprise a protein capsid, for in vivo delivery of RNA to a vertebrate cell, wherein (a) the particle is a liposome and comprises a delivery material encapsulating a self-replicating RNA molecule which encodes an immunogen, wherein the immunogen is a surface polypeptide and can elicit an immune response in vivo against a bacterium, a virus, a fungus or a parasite, and (b) the RNA includes no modified nucleotides, and optionally includes a 5' cap. 
Nevirionska čestica koja ne sadrži proteinsku kapsidu, za in vivo unos RNA u stanicu kralježnjaka, naznačena time što (a) čestica je liposom i sadrži materijal za unos koji inkapsulira samoreplicirajuću molekulu RNA koja kodira imunogen, gdje je imunogen površinski polipeptid i može izazvati imunosni odgovor in vivo protiv bakterije, virusa, gljivice ili parazita, te (b) RNA ne sadrži modificirane nukleotide, a može sadržavati 5′ kapu.
The particle of claim 1, wherein the liposome comprises a lipid with a cationic head group. 
Čestica u skladu s patentnim zahtjevom 1, naznačena time što liposom sadrži lipid s kationskom glavnom skupinom.
The particle of claim 1, wherein the liposome comprises a lipid with a zwitterionic head group. 
Čestica u skladu s patentnim zahtjevom 1, naznačena time što liposom sadrži lipid s zwitter-ionskom glavnom skupinom.
The particle of claim 5, wherein the polymerase is an alphavirus replicase. 
Čestica u skladu s patentnim zahtjevom 5, naznačena time što je polimeraza alfavirusna replikaza.
The particle of any preceding claim, wherein the immunogen can elicit an immune response in vivo against: 
Čestica u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što imunogen može izazvati imunosni odgovor in vivo protiv:
A pharmaceutical composition comprising a particle of any preceding claim. A delivery device containing the pharmaceutical composition of claim 11. The particle of any of claims 1-10, or the pharmaceutical composition of claim 11, or the delivery device of claim 12, for use in a method for raising a protective immune response in a vertebrate, comprising the step of administering to the vertebrate an effective amount of said particle, or said pharmaceutical composition. 
Čestica u skladu s bilo kojim od patentnih zahtjeva 1-10, ili farmaceutski pripravak u skladu s patentnim zahtjevom 11, ili sredstvo za unos u skladu s patentnim zahtjevom 12, naznačeni time što su namijenjeni upotrebi u postupku izazivanja zaštitnog imunosnog odgovora kod kralježnjaka, koji se sastoji u koraku primjene na kralježnjaku djelotvorne količine navedene čestice, ili navedenog farmaceutskog pripravka.
halogenation or sulfinylation of the compound of formula (III) to produce a compound of formula (IV); wherein X is halo, or -SO-R5, and R5 is a group selected from C6-10aryl or heteroaryl, each group being optionally substituted by one or more substituents independently selected from chloro or C1-4alkyl; 
halogeniranje ili sulfoniranje spoja formule (III) kako bi se dobio spoj formule (IV); pri čemu je X halo, ili -SO-R5, i R5 je skupina odabrana od C6-10arila ili heteroarila, svaka skupina po izboru je supstituirana sa jednim ili više supstituenata neovisno odabranih od kloro ili C1-4alkila;
dehalogenation or desulfinylation of the compound of formula (IV) to produce compound of formula (V); and 
dehalogeniranje ili desulfoniranje spoja formule (IV) kako bi se dobio spoj formule (V); i [image]
The process according to claim 1, wherein step (b) is a sulfinylation and the sulfinylation is performed by reacting the compound of formula (III) with a base and with a sulfinylation reagent. 
Postupak prema zahtjevu 1, u kome je korak (b) sulfoniranje a sulfoniranje se izvodi reakcijom spoja formule (III) sa bazom i reagensom za sulfoniranje.
The process according to claim 1 or 2 wherein step (b) is a sulfinylation and the sulfinylation reagent is methyl 2-pyridinesulfinate, methyl benzenesulfinate, methyl 4-methyl-benzenesufinate, methyl 4-chloro-benzene sulfinate. 
Postupak prema zahtjevima 1 ili 2, u kome je korak (b) sulfoniranje a reagens za sulfoniranje je metil 2-piridinsulfinat, metil benzensulfinat, metil 4-metil-benzensulfinat, metil 4-kloro-benzen sulfinat.
The process according to claim 2 or 3, wherein the base used in the sulfinylation step is selected from the group comprising potassium hydride, potassium terbutylate, sodium hydride, sodium terbutylate and a mixture thereof. 
Postupak prema zahtjevima 2 ili 3, u kome je baza korištena u koraku sulfoniranja odabrana iz skupine koja obuhvaća kalijev hidrid, kalijev terbutilat, natrijev hidrid, natrijev terbutilat i njihove smjese.
The process according to claim 1, wherein step (b) is a halogenation and the halogenation is performed by reacting the compound of formula (III) with a halogenating reagent. 
Postupak prema zahtjevu 9, u kome je korak (b) halogeniranje a halogeniranje se izvodi reakcijom spoja formule (III) sa reagensom za halogeniranje.
The process according to claim 1 or 5 wherein step (b) is a bromination and the brominating reagent is selected from the group comprising copper(II) bromide, bromine, and pyridine bromine perbromine. 
Postupak prema zahtjevima 1 ili 5, u kome je korak (b) bromiranje a reagens za bromiranje odabran je iz skupine koja obuhvaća bakar (II) bromid, brom, i piridin brom perbromin.
The process according to claim 8, wherein the base is selected from the group comprising imidazole, collidine, 2,6-lutidine, triethylamine, or 1,8-diazabicyclo[5.4.0]undec-7-ene. 
Postupak u skladu sa zahtjevom 8, u kome je baza odabrana iz skupine koja obuhvaća imidazol, kolidin, 2,6-lutidin, trietilamin, ili 1,8-diazabiciklo [5.4.0]undek-7-en.
o is free of surfactants with the exception of polysorbate 80; and o is free of phosphate buffering agents/systems. 
o je bez surfaktanta uz iznimku polisorbata 80; i o je bez fosfatnih puferskih sredstava/sustava.
The liquid pharmaceutical composition as claimed in claim 1, wherein the composition is free of amino acids. 
Tekući farmaceutski pripravak prema zahtjevu 1, naznačen time da je pripravak bez amino kiselina.
The drug deliver device as claimed in claim 7, wherein the drug delivery device is a vial, ampoule, syringe, injection pen, or an intravenous bag comprising the liquid pharmaceutical composition. 
Uređaj za dostavu lijeka prema zahtjevu 7, naznačen time da uređaj za dostavu lijeka je bočica, ampula, injekcija, olovka za ubrizgavanje, vrećica za intravensko davanje koja sadrži tekući farmaceutski pripravak.
is an amino protecting groups or acetyl; 
je amino zaštitna grupa ili acetil;
is hydrogen or a hydroxyl protecting group, preferably a hydroxyl protecting group; 
je vodik ili hidroksilna zaštitna grupa, poželjno hidroksilna zaštitna grupa;
The process of claim 4, wherein P1 is acetyl; P4 is a hydroxyl protecting group, P6 is hydrogen or an amino protecting groups; and P8 is an amino protecting group. 
Postupak iz patentnog zahtjeva 1, pri čemu je P1 acetil; P4 je hidroksilna zaštitna grupa; P6 je vodik ili amino zaštitna grupa; i P8 je amino zaštitna grupa.
A liquid process for preparing Degarelix comprising a process according to claim 1 or 2, followed by a process comprising the step of subjecting the decapeptide represented by formula II or a salt or solvate thereof to a treatment with a cleaving agent for removing the protecting groups P4, P6 and P8. 
Tekući postupak za pripravu degareliksa obuhvaća postupak u skladu s patentnim zahtjevom 1 ili 2, koji slijedi postupak koji obuhvaća korak podvrgavanja dekapeptida predstavljenog formulom II ili njegove soli ili solvata tretiranju agensom za cijepanje zbog uklanjanja zaštitnih grupa P4, P6 i P8.
is hydrogen or a hydroxyl protecting group, preferably a hydroxyl protecting group; 
vodik ili hidroksilna zaštitna grupa, poželjno hidroksilna zaštitna grupa;
is hydrogen or an amino protecting groups; preferably an amino protecting groups; and 
je vodik ili amino zaštitna grupa; poželjno amino zaštitna grupa; i
The process according to claim 7 wherein PN is benzyloxycarbonyl which is removed by hydrogenating the compound (PN)AA4(P4)-AA5-AA6(P6)-AA7-AA8(P8)-AA9-AA10-NH2 in the presence of a Pd/C catalyst. 
Postupak u skladu s patentnim zahtjevom 5 pri čemu je PN benziloksikarbonil koji se uklanja hidrogenacijom tvari AA4(P4)-AA5-AA6(P6)-AA7-AA8(P8)-AA9-AA10-NH2 u prisutnosti Pd/C katalizatora.
The process of any one of claims 5 or 6, followed by the process of any one of claims 1 to 3. 
Postupak iz bilo kojeg od patentnih zahtjeva 5 ili 6, kojeg slijedi postupak iz bilo kojeg od patentnih zahtjeva 1 do 3.
The process of one or more of the preceding claims, wherein the pH is kept below 9, preferably below 8. 
Postupak iz jednog ili više od prethodnih patentnih zahtjeva, pri čemu se pH održava ispod 9, poželjno ispod 8.
Polypeptide compounds represented by the following formulae: 
Polipeptidne tvari predstavljene sljedećim formulama:
is an amino protecting group, and PN is a protecting group. 
je amino zaštitna grupa, i PN je zaštitna grupa.
The composition for the use of claim 10 or 11, wherein the factor Xa inhibitor is selected from the group consisting of fondaparinux, idraparinux, biotinylated idraparinux, enoxaparin, fragmin, NAP-5, rNAPc2, tissue factor pathway inhibitor, DX-9065a, YM-60828, YM-150, apixaban, rivaroxaban, PD-348292, otamixaban, DU-176b, LY517717, GSK913893, razaxaban, low molecular weight heparin, betrixaban or a pharmaceutically acceptable salt thereof, and combinations thereof. 
Pripravak za uporabu prema zahtjevu 10 ili 11, naznačen time da je inhibitor faktora Xa odabran iz skupine koju čine fondaparinuks, idraparinuks, biotinilirani idraparinuks, enoksaparin, fragmin, NAP-5, rNAPc2, inhibitor faktora tkivnog puta, DX-9065a, YM-60828, YM-150, apiksaban, rivaroksaban, PD-348292, otamiksaban, DU-176b, LY517717, GSK913893, razaksaban, heparin niske molekularne težine, betriksaban ili njihova farmaceutski prihvatljiva sol, te njihove kombinacije.
compressing the moistened dose to form a tablet (C) having a desired shape; and 
formiranje doze vlažne mješavine praha kompresijom kako bi se formirala tableta (C) željenog oblika;
The method as claimed in claim 1, wherein the microwave frequency ranges from 0.915 to 5.8 GHz. 
Postupak sukladno zahtjevu 5, pri čemu je opseg frekvencije mikrovalova od 0,915 do 5,8 GHz.
The method as claimed in claim 1, wherein a microwave irradiation with said electromagnetic wave beam is performed in a substantially constant fashion, for a predetermined time (T), ranging from a few seconds to 2 minutes. 
Postupak sukladno jednom od zahtjeva 5 i 6, pri čemu je iradijacija mikrovalova izvedena na supstancijalno konstantni način, kroz prethodno određeno vrijeme (T), opsega od 2 minute, i poželjno manje od 1 minute.
The method as claimed in claim 1, wherein said moistening step c) is carried out by adding a predetermined amount of water to the product powder, followed by the step of homogenizing, to obtain a substantially uniform moistened mixture. 
Postupak sukladno zahtjevu 1, pri čemu se korak vlaženja c) izvodi dodavanje prethodno određene količine vode praškastom proizvodu, i po mogućnosti dodavanjem vezivnih sredstava, praćeno korakom homogenizacije, koji se izvodi miješanjem, radi dobivanja u osnovi jednolične vlažne mješavine.
The method as claimed in claim 1, wherein said step f) of supplying an amount of energy is followed by a rest step h) for the tablet, which is in turn followed by a step i) in which the tablet undergoes individual or multiple packaging. 
Postupak sukladno jednom ili više prethodnih zahtjeva, pri čemu je korak opskrbe energijom f) praćen kratkim korakom odmora h) tablete, koji je praćne korakom u kojem posljednja prolazi postupak pojedinačnog ili pakiranja više tableta zajedno i).
The parasiticidal composition for use according to claim 15 wherein the endoparasitic infection is with a helminth selected from the group consisting of Anaplocephala (Anoplocephala), Ancylostoma, Anecator, Ascaris, Brugia, Bunostomum, Capillaria, Chabertia, Cooperia, Cyathostomum, Cylicocyclus, Cylicodontophorus, Cylicostephanus, Craterostomum, Dictyocaulus, Dipetalonema, Dipylidium, Dirofilaria, Dracunculus, Echinococcus, Enterobius, Fasciola, Filaroides, Habronema, Haemonchus, Metastrongylus, Moniezia, Necator, Nematodirus, Nippostrongylus, Oesophagostumum, Onchocerca, Ostertagia, Oxyuris, Paracaris, Schistosoma, Strongylus, Taenia, Toxocara, Strongyloides, Toxascaris, Trichinella, Trichuris, Trichostrongylus, Triodontophorous, Uncinaria, Wuchereria, and combinations thereof. 
Ariloazol-2-il-cijanoetilamin za uporabu prema zahtjevu 11, naznačen time, da je endoparazitna infekcija uzrokovana helmintom odabranim iz skupine koju čine: Anaplocephala (Anoplocephala), Ancylostoma, Anecator, Ascaris, Brugia, Bunostomum, Capillaria, Chabertia, Cooperia, Cyathostomum, Cylicocylclus, Cylicodontophorus, Cylicostephanus, Craterostomum, Dictyocaulus, Dipetalonema, Dipylidium, Dirofilaria, Dracunculus, Echinococcus, Enterobius, Fasciola, Filaroides, Habronema, Haemonchus, Metastrongylus, Moniezia, Necator, Nematodirus, Nippostrongylus, Oesophagostumum, Onchocerca, Ostertagia, Oxyuris, Paracaris, Schistosoma, Strongylus, Taenia, Toxocara, Strongyloides, Toxascaris, Trichinella, Trichuris, Trichostrongylus, Tridontophorus, Uncinaria, Wuchereria, i njihove kombinacije.